Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
The net profit margin is N/A as of Tuesday, October 6, 2026.
NET PROFIT MARGIN
N/A
Market Cap
$1.52B
Net Profit Margin
12.02%
TTM Avg
-7.78%
3Y Avg
-15.24%
5Y Avg
-11964.64%
Market Cap
$1.46B
Net Profit Margin
82.37%
TTM Avg
-82.37%
3Y Avg
-592.43%
5Y Avg
-414.63%
Market Cap
$1.57B
Net Profit Margin
-16.75%
TTM Avg
-1.75%
3Y Avg
-3.69%
5Y Avg
-6.61%
Market Cap
$1.43B
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$1.65B
Net Profit Margin
-13.50%
TTM Avg
-22.64%
3Y Avg
-31.77%
5Y Avg
-40.07%
Market Cap
$1.65B
Net Profit Margin
10.82%
TTM Avg
2.93%
3Y Avg
-1.36%
5Y Avg
-5.99%
Market Cap
$1.34B
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | $1.51B | N/A | N/A | N/A | N/A |
| GH Research PLC (GHRS)vs › | $1.52B | 0.00% | 0.00% | 0.00% | 0.00% |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.52B | 12.02% | -7.78% | -15.24% | -11964.64% |
| AnaptysBio, Inc. (ANAB)vs › | $1.46B | 82.37% | -82.37% | -592.43% | -414.63% |
| Certara, Inc. (CERT)vs › | $1.57B | -16.75% | -1.75% | -3.69% | -6.61% |
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs › | $1.43B | 0.00% | 0.00% | 0.00% | 0.00% |
| Alphatec Holdings, Inc. (ATEC)vs › | $1.65B | -13.50% | -22.64% | -31.77% | -40.07% |
| ANI Pharmaceuticals, Inc. (ANIP)vs › | $1.65B | 10.82% | 2.93% | -1.36% | -5.99% |
| Alpha Tau Medical Ltd (DRTS)vs › | $1.34B | 0.00% | 0.00% | 0.00% | 0.00% |
| ArriVent BioPharma, Inc. (AVBP)vs › | $1.33B | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Margin
N/A
Net Profit Margin
N/A
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
